NYSE: SYKStryker Corp Stock
$380.23+7.57 (+2.03%)
Updated Feb 20, 2026
SYK Price
$380.23
Fair Value Price
N/A
Market Cap
$145.51B
52 Week Low
$329.16
52 Week High
$404.87
P/E
44.79x
P/B
6.49x
P/S
5.35x
PEG
1.48x
Dividend Yield
0.89%
Revenue
$25.12B
Earnings
$3.25B
Gross Margin
64%
Operating Margin
20.39%
Profit Margin
12.9%
Debt to Equity
1.13
Operating Cash Flow
$5B
Beta
0.85
Next Earnings
N/A
Ex-Dividend
Mar 31, 2026
Next Dividend
Apr 30, 2026
SYK Overview
Stryker Corporation is a medical technology company that operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. It also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company was founded in 1941 and is headquartered in Kalamazoo, MI.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SYK's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
SYK
Ranked#19 of 103
Ranked#19 of 103
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.58 | A | |
| $24.26 | A | |
| $28.72 | A |
Be the first to know about important SYK news, forecast changes, insider trades & much more!
SYK News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SYK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYK ($380.23) is trading above its intrinsic value of $145.87, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYK is poor value based on its earnings relative to its share price (44.79x), compared to the US market average (44.63x)
P/E vs Market Valuation
SYK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more SYK due diligence checks available for Premium users.
Valuation
SYK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
44.79x
Industry
26.09x
Market
44.63x
SYK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SYK is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SYK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.49x
Industry
3.65x
SYK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYK price to earnings growth (PEG)
For valuing profitable companies with growth potential
SYK is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SYK's financial health
Profit margin
Revenue
$7.2B
Net Income
$849.0M
Profit Margin
11.8%
SYK's Earnings (EBIT) of $5.12B... subscribe to Premium to read more.
Interest Coverage Financials
SYK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$47.8B
Liabilities
$25.4B
Debt to equity
1.13
SYK's short-term assets ($14.76B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYK's long-term liabilities ($17.63B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SYK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.1B
Investing
-$305.0M
Financing
-$1.1B
SYK's operating cash flow ($5.04B)... subscribe to Premium to read more.
Debt Coverage Financials
SYK vs Medical Device Stocks
Stryker Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.